Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 9/20 | 0.80 |
| ▸ | PRKAG1 | P54619 | 9/20 | 0.80 |
| ▸ | PRKAA2 | P54646 | 9/20 | 0.80 |
| ▸ | PRKAA1 | Q13131 | 9/20 | 0.80 |
| ▸ | PRKAG3 | Q9UGI9 | 9/20 | 0.80 |
| ▸ | PRKAG2 | Q9UGJ0 | 9/20 | 0.80 |
| ▸ | PRKAB1 | Q9Y478 | 9/20 | 0.80 |
| ▸ | FLT1 | P17948 | 10/20 | 0.70 |
| ▸ | KDR | P35968 | 10/20 | 0.70 |
| ▸ | ACVR1 | Q04771 | 5/20 | 0.70 |
| ▸ | BMP4 | P12644 | 5/20 | 0.70 |
| ▸ | LCK | P06239 | 5/20 | 0.70 |
| ▸ | SRC | P12931 | 5/20 | 0.70 |
| ▸ | EPHA2 | P29317 | 5/20 | 0.70 |
| ▸ | RPS6KA1 | Q15418 | 5/20 | 0.70 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.70 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.70 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.70 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.70 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17442460 | 0.99 | PRKAB2 (0.82) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL16111438 | 0.88 | PRKAB2 (0.66) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL17442468 | 0.88 | PRKAB2 (0.62) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL17442165 | 0.84 | PRKAB2 (0.57) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL11953875 | 0.84 | KDR (0.83) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL16112356 | 0.83 | ACVR1 (0.66) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| Dorsomorphin SCHEMBL463155 | 0.83 | KDR (1.00) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL13126025 | 0.83 | KDR (0.81) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL13126023 | 0.83 | FLT1 (0.81) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL13126029 | 0.83 | FLT1 (0.81) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| US-9682983-B2 | BMP inhibitors and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682983-B2 | BMP inhibitors and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2016-02-18 | — | — | US | disclosed |
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2016-02-18 | — | — | US | disclosed |
| WO-2016011019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016011019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20100240647-A1 | Treatment of Alzheimer's Disease and Related Conditions | MERCK & CO., INC. | 2010-09-23 | — | — | US | disclosed |
| EP-1981509-B1 | Pyrazolo[1,5-a]pyrimidine derivatives for use in treatment of Alzheimer's disease and related conditions | MERCK SHARP & DOHME (GB) | 2010-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240647-A1 | Treatment of Alzheimer's Disease and Related Conditions | MAPT, MAP2, TTBK1 | PRKAB2 342/4885PRKAG1 249/4885PRKAA2 742/4885 |
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | BMP1, BMPR2, BMP2 | PRKAB2 3101/4885PRKAG1 3344/4885PRKAA2 4365/4885 |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | BMP1, BMP2, BMPR2 | PRKAB2 1983/4885PRKAG1 2129/4885PRKAA2 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.